Acquisition of chemoresistance following discontinuous exposures to cisplatin is associated in ovarian carcinoma cells with progressive alteration of FAK, ERK and p38 activation in response to treatment
- 1 June 2006
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 101 (3) , 507-519
- https://doi.org/10.1016/j.ygyno.2005.11.017
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Cellular processing of platinum anticancer drugsNature Reviews Drug Discovery, 2005
- Long‐term activation of SAPK/JNK, p38 kinase and fas‐L expression by cisplatin is attenuated in human carcinoma cells that acquired drug resistanceInternational Journal of Cancer, 2004
- Hypermethylation of the PTEN gene in ovarian cancer cell linesCancer Letters, 2004
- Cisplatin: mode of cytotoxic action and molecular basis of resistanceOncogene, 2003
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003
- AKT2 Inhibition of Cisplatin-induced JNK/p38 and Bax Activation by Phosphorylation of ASK1Journal of Biological Chemistry, 2003
- Caspase 3-Mediated Focal Adhesion Kinase Processing in Human Ovarian Cancer Cells: Possible Regulation by X-Linked Inhibitor of Apoptosis ProteinGynecologic Oncology, 2002
- Multiple drug resistance in the human ovarian carcinoma cell line OAW42-AEuropean Journal Of Cancer, 1993
- Features of apoptotic cells measured by flow cytometryCytometry, 1992
- Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation.Journal of Clinical Investigation, 1991